Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
Status:
Recruiting
Trial end date:
2023-05-30
Target enrollment:
Participant gender:
Summary
The aim of the present study is to compare the efficacy of liraglutide vs.
naltrexone/bupropion on metabolic and cardiovascular risk markers, weight loss, as well as
the postprandial secretion of gastrointestinal hormones involved in hunger and satiety, after
a test meal. The study will include 40 patients, who will further be divided into two
treatment groups (20 patients on liraglutide vs. 20 patients on naltrexone/bupropion). The
patients will be examined at baseline, 3 and 6 months after the treatment initiation.